An open label, prospective, double arm clinical trial to compare the efficacy and safety of super bioavailable itraconazole capsules and itraconazole capsules in the management of corporis/cruris/faciei.

Omega Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Both male and female patients aged >= 18 years and <= 60 years.
•2.Patients with diagnosis of tinea corporis/cruris/faciei requiring systemic antifungal therapy.
•3.Female of child bearing potential, who is prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., condom with spermicide, IUD, oral, injected, transdermal or implanted hormonal contraceptives).
•4.Patients who are ready to give written informed consent, which includes a commitment to comply with all requirements, specified in the study protocol, among others a negative urine pregnancy test in the case of women of childbearing age.
•5.Patients who the study staff deems reliable and mentally competent to carry out the study.

•1.Pregnant or nursing females.
•2.Patients with known hypersensitivity to the study drugs.
•3.Patients with immunosuppressive disease or on immunosuppressive drugs.
•4.Patients with liver dysfunction.
•5.Patients with a history of seizures
•6.Evidence of clinically significant disease (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the Investigator(s) could affect the subjectâ??s safety or interfere with the study assessments.
•7.Any history of or concomitant medical condition that in the opinion of the Investigator(s) would compromise the subjectâ??s ability to safely complete the study.
•8.History of drug or alcohol dependency or abuse within approximately the last 2 years.
•9.Currently enrolled in another clinical study or used any investigational drug or device within 30 days preceding informed consent or were scheduled to participate in another clinical study that involved an investigational product or investigational drug during the course of this study.
•10.Patients with malignancy.
•11.Any patient whom the investigator judged to be inappropriate for this study.

发起方

Omega Hospital